ArticleCureus2025
Mazabraud Syndrome: A Case Report With 23 Years of Follow-Up.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of Mazabraud's syndrome identified by FDG PET/CT.EJNMMI reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mazabraud syndrome is a rare condition characterized by the coexistence of fibrous dysplasia (FD) and intramuscular myxomas. A 46-year-old woman, initially diagnosed with polyostotic FD at the age of 23, developed a palpable mass on her left arm 15 years later, which proved to be an intramuscular myxoma. A diagnosis of Mazabraud syndrome was made. Over the following two decades, she developed additional intramuscular myxomas. The patient denied surgical excision of the soft tissue lesions and was managed conservatively for symptomatic FD. Radiologic imaging, including MRI and ultrasound, played a crucial role in the diagnosis and the assessment of disease progression. Although both FD and myxomas are benign musculoskeletal abnormalities, close follow-up of the patients is essential to monitor changes in the number, distribution, and extent of lesions that may occasionally undergo malignant transformation. This case underscores the importance of early detection and long-term follow-up of patients with FD who may present with, or eventually develop, intramuscular myxomas, comprising Mazabraud syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.